Pharma Focus Europe


The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

Relief Therapeutics and Acer Therapeutics Forge Exclusive License Agreement for OLPRUVA™ (ACER-001)

Thursday, August 31, 2023

RELIEF THERAPEUTICS Holding SA SWXRLF has recently entered into an exclusive licensing agreement with Acer Therapeutics Inc for the development and commercialization of OLPRUVA sodium phenylbutyrate

Laurent Pharmaceuticals Receives Approval From Health Canada to Commence Phase 2/3 Clinical Trial for Long COVID

Wednesday, August 30, 2023

Laurent Pharmaceuticals Inc headquartered in Montreal has received approval from Health Canada to initiate the ESSOR trial a Phase randomized placebocontrolled study

European Commission Grants Approval to Roche's Evrysdi for Infants Under Two Months Old With Spinal Muscular Atrophy (SMA)

Wednesday, August 30, 2023

Roche SIX RO ROG OTCQX RHHBY has received approval from the European Commission to expand the use of Evrysdi risdiplam within the European Union EU

Cantex Pharmaceuticals Initiates Investigator-initiated Phase 2 Clinical Trial to Study Azeliragon Combined with Stereotactic Radiosurgery for Brain Metastases Treatment

Tuesday, August 29, 2023

Cantex Pharmaceuticals a clinicalstage pharmaceutical company focused on developing innovative therapies for cancer and lifethreatening conditions has announced the initiation of a Phase clinical trial

Sandoz Successfully Concludes Acquisition of Leading Antifungal Agent Mycamine® From Astellas, Further Strengthening Global Anti-infectives Portfolio

Monday, August 28, 2023

Sandoz a major player in the field of generic and biosimilar medicines has successfully concluded the acquisition of the global brand rights for Mycamine micafungin sodium a leading systemic antifungal agent This acquisition was made from Astellas

Ceapro and Symrise Prolong Exclusive Global Supply and Distribution Agreement for Active Ingredients

Saturday, August 26, 2023

Ceapro Inc publicly traded as CZO on TSXV and as CRPOF on OTCQX a burgeoning biotechnology enterprise specializing in the development and commercialization of active ingredients for the healthcare and cosmetic sectors has announced a significant amen...

Maplight Therapeutics Has Announced the Successful Completion of the Second Phase 1 Clinical Trial for Their Novel Muscarinic Receptor Agonist, ML-007

Friday, August 25, 2023

MapLight Therapeutics a clinicalstage biopharmaceutical company has successfully completed a second Phase clinical trial for its novel compound ML This compound is designed to target MM muscarinic receptor agonists with the aim of addressing brain

Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 in Treatment of Claudin-1 Positive HNSCC

Friday, August 25, 2023

Alentis Therapeutics a clinicalstage biotechnology company has been granted Fast Track development status by the US Food and Drug Administration FDA for their drug candidate ALEC This drug is being developed to treat patients with recurrent or metast...

Paradigm Therapeutics Acquires Advanced Late-stage "Breakthrough Therapy" for Treating All Subtypes of Epidermolysis Bullosa (EB)

Wednesday, August 23, 2023

Paradigm Therapeutics Inc a prominent biopharmaceutical firm has successfully concluded the acquisition of the global rights to SD from Amicus Therapeutics SD represents a topical remedy designed to address all subtypes of Epidermolysis Bullosa EB

Ventus Therapeutics Launches Phase 1 Clinical Trial for VENT-02: a New Orally Administered NLRP3 Inhibitor with Enhanced Brain Penetration

Wednesday, August 23, 2023

Ventus Therapeutics has commenced a Phase clinical trial for VENT a groundbreaking oral NLRP inhibitor engineered to address neuroinflammatory diseases Marcelo Bigal MD PhD the CEO of the company expressed enthusiasm about reaching this pivotal junc...